Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

chromium picolinate for Nardil weight gain?

Posted by Chairman_MAO on May 12, 2009, at 15:43:45

Check out this abstract that I found ...
I've been taking 200mcg of chromium
picolinate with each dose of Nardil,
and it really seems to help curb
carbohydrate cravings. There's no particular
rationale for my taking it four times per day
other than it matches when I take the
Nardil.

I had a glucose tolerance test done once; the
result was, if I recall correctly, that I was
almost clinically hypoglycemic. On the other
hand, according to Wikipedia, anyway, an oral glucose
tolerance test is anything but robust. I was not
on Nardil when this test was done.

Has anyone tried chromium supplementation
with Nardil?

--Chairman_MAO

J Clin Psychiatry. 1997 Jun;58(6):274.

Treatment of depression in patients with diabetes mellitus.

Goodnick PJ, Henry JH, Buki VM.

Department of Psychiatry, University of Miami, FL 33136, USA.


BACKGROUND: Depression occurs frequently in patients with diabetes mellitus.
Little has been published on the epidemiology, biochemistry, and treatment of
depression in diabetic patients. METHOD: We searched MEDLINE for literature from

January 1966 to July 1993 and cross-referenced the terms diabetes, glucose,
hyperglycemia, or hypoglycemia, with each of the following: antidepressants,
monoamine oxidase inhibitors, tricyclic antidepressants, fluoxetine, paroxetine,

sertraline, and bupropion. The results reviewed were 20 papers on epidemiology,
15 papers on neurochemicals and glucose control, and 28 papers on antidepressants
and factors of importance to diabetics. Additional papers were selected from the

reference lists of the retrieved articles. RESULTS: The prevalence of depression
in diabetics varies from 8.5% to 27.3%. Severity of depression correlates strongly with many symptoms of diabetes mellitus. The hydrazine monoamine oxidase

inhibitors (MAOIs), e.g., phenelzine, potentiate animal models of hypoglycemia
due to direct influence on gluconeogenesis secondary to the hydrazine structure,
not to MAOI considerations. Dopamine and norepinephrine influences in these

models appear to be hyperglycemic. Serotonergic influences, in the presence of
MAOIs, which decrease serotonin metabolism, are in contrast hypoglycemic.
Clinically, MAOI use is limited by the possible severity of the induced
hypoglycemia, induced weight gain, and required diets.


Share
Tweet  

Thread

 

Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:Chairman_MAO thread:895390
URL: http://www.dr-bob.org/babble/20090505/msgs/895390.html